These hypotheses suggest that eliminating amyloid and hyperphosphorylated tau could improve cognition in AD patients, while major drugs targeting amyloid and tau proteins could not improve cognitive functions in clinical trials. The gene discussed is MAPT; the disease is Alzheimer disease.